Amberstone Biosciences’ transformative immunotherapeutics eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. Traditional therapies can be extremely effective at destroying tumors. However, the high dosage required for efficacy often has devastating effects on surrounding tissues. Our technology (T-MATEs™) allows us to target only the tumor without damaging healthy tissues.
Our AmberFlow™ discovery platform, driven by proprietary single-cell microfluidics technology, significantly improves target discovery throughput and efficiency over traditional approaches.